BFM
REGN icon

Boothbay Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Boothbay Fund Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-98
Closed -$4.79M – 1087
2020
Q1 		$4.79M Buy
+98
New +$40.4K 0.4% 52
2018
Q3 		– Sell
-476
Closed -$16.4M – 922
2018
Q2 		$16.4M Buy
+476
New +$149K 1.43% 12

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Boothbay Fund Management's REGN Position: Q2 2026 in Review

Boothbay Fund Management increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q2 2026, buying an estimated $231K and bringing the position to 3,312 shares worth $2.07M. The position accounts for 0.03% of the portfolio, ranked #706.

Boothbay Fund Management first reported a position in REGN in Q2 2019 and has held it in 15 quarters since. The position peaked at $8.82M in Q4 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Boothbay Fund Management held 3,312 shares of Regeneron Pharmaceuticals worth $2.07M as of Q2 2026.
  • Boothbay Fund Management bought 340 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $231K.
  • Regeneron Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #706 holding.
  • Boothbay Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 15 quarters since.
  • Boothbay Fund Management's Regeneron Pharmaceuticals position peaked at $8.82M in Q4 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.